Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine and other therapeutics. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a short-wear-time transdermal patch that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone receptor-positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: radiuspharm.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2024 | $22.00 | Neutral | Goldman |
| 5/30/2024 | Sell → Neutral | Seaport Research Partners | |
| 2/28/2024 | $17.50 | Neutral → Sell | Seaport Research Partners |
| 12/14/2023 | Neutral | Seaport Research Partners | |
| 6/8/2022 | $8.00 | Underperform → Neutral | BofA Securities |
| 5/23/2022 | $7.00 | Mkt Perform | SVB Leerink |
| 12/10/2021 | $18.00 → $7.00 | Equal-Weight → Underweight | Morgan Stanley |
| 12/10/2021 | $33.00 → $12.00 | Buy → Neutral | Goldman Sachs |
| 12/9/2021 | $30.00 → $20.00 | Market Perform | SVB Leerink |
| 12/9/2021 | $23.00 → $10.00 | Neutral | HC Wainwright & Co. |
Submission status for RADIUS HEALTH INC's drug TYMLOS (SUPPL-13) with active ingredient ABALOPARATIDE has changed to 'Approval' on 12/19/2022. Application Category: NDA, Application Number: 208743, Application Classification: Efficacy
Submission status for RADIUS HEALTH INC's drug TYMLOS (SUPPL-10) with active ingredient ABALOPARATIDE has changed to 'Approval' on 12/22/2021. Application Category: NDA, Application Number: 208743, Application Classification: Efficacy
Submission status for RADIUS HEALTH INC's drug TYMLOS (SUPPL-10) with active ingredient ABALOPARATIDE has changed to 'Tentative Approval' on 10/28/2021. Application Category: NDA, Application Number: 208743, Application Classification: Efficacy
Submission status for RADIUS HEALTH INC's drug TYMLOS (SUPPL-9) with active ingredient ABALOPARATIDE has changed to 'Approval' on 09/20/2021. Application Category: NDA, Application Number: 208743, Application Classification: Efficacy